Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg plus intravenous methylprednisolone versus IVIg plus placebo as first-line treatment for CIDP
ISRCTN15893334Phase 3Completed
- Sponsor
- Academic Medical Center
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing IVIg + methylprednisolone with IVIg + placebo (2 arms). Primary endpoint: Number of patients in remission at 1 year. Started Feb 2018; status: completed.
02
Drugs
immune globulinmethylprednisolone
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on ISRCTN15893334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15893334.